论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Xiao W, Wang X, Wang T, Xing J
Received 24 August 2018
Accepted for publication 6 October 2018
Published 20 November 2018 Volume 2018:10 Pages 5951—5964
DOI https://doi.org/10.2147/CMAR.S185270
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Dr Antonella D'Anneo
Background and aim: Tripartite
motif containing (TRIM) family protein has been involved in multiple
pathogenesis of cancers. TRIM2 is a member of the family, and its role in clear
cell renal cell carcinoma (ccRCC) remains to be unclarifid. Here, we showed the
clinical value and biological role of TRIM2 in ccRCC.
Methods: ROC
curves analyzed the clinicopathological parameters, Kaplan-Meier survival
analysis determined the correlation of OS and DFS time, multivariate analysis
demonstrated the prognostic indicator in overall survival and disease-free
survival of ccRCC with TRIM2 expression in The Cancer Genome Atlas Kidney Clear
Cell Carcinoma (TCGA-KIRC) database. Western blotting and immunohistochemistry
were used to check the level of TRIM2 expression. Gain-of-function assay by
exogenous overexpression of TRIM2 studied the biological role of TRIM2 in renal
cell carcinoma cells.
Results: TRIM2
expression was associated with various clinicopathologicalfactors and lower
TRIM2 expression was interrelated to a poor prognosis. The levels of TRIM2
expression were also scanty in ccRCC tissues and renal cancer cell lines than
in normal control. The biological role of TRIM2 in ccRCC was identifid by
bioinformatics analysis and functional analysis. Exogenous overexpression of
TRIM2 with the gain-of-function assay in renal cell carcinoma cells showed that
the cell proliferation, migration, and invasion were signifiantly
suppressed.
Conclusion: These results
showed that TRIM2 acted as an antitumor gene and a specifi prognostic indicator
for patients with ccRCC, which indicated that positive modulation of TRIM2
might be a novel treatment strategy for ccRCC.
Keywords: TRIM2,
ccRCC, tumor suppressor, prognostic indicator
